Oncology
November 3, 2023
Localized Airway Delivery of Interleukins-12 and -2 via Inhalation of a Replication-defective HSV-1-based Therapy for the Treatment of Primary and Secondary Lung Tumors
Summary: During the SITC Annual Meeting & Pre-Conference Programs in San Diego, California from November 1-5, data was presented on preclinical data in multiple oncology models. One presentation showed that non-invasive inhalation of vector-encoded IL-2 and IL-12 was found to be both safe and effective in treating lung tumors in a metastasis model, resulting in long-term survival after single or repeated cancer cell challenge, suggestive of prolonged adaptive immunity.
- Presentation 975.8 KB
November 3, 2023
A Replication-defective, HSV-1 Based Gene Therapy for Localized Delivery of Combinatorial Interleukins-12 and -2 for the Treatment of Cutaneous Malignancies
Summary: During the SITC Annual Meeting & Pre-Conference Programs in San Diego, California from November 1-5, data was presented on preclinical data in multiple oncology models. One presentation showed combinatorial IL-2 and IL-12 expressed from Krystal’s platform technology provided a synergistic effect in a melanoma model, suppressing treated and non-treated tumor outgrowth, enhancing survival, and eliciting a durable memory response sufficient for recurrent tumor control.
- Presentation 1 MB